Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
River Stone Biotech Aps currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and is situated within 1 distinct art unit. The presence of 1 pending matter suggests a specific prosecution phase for the company in this technological sector.
The busiest examiner for the portfolio is SAIDHA, TEKCHAND, who is responsible for 1 busiest examiner pending action. This 1 examiner holds the responsibility for the company's current pending applications. Practitioners should analyze the past decisions of this 1 individual within the Biotechnology & Pharmaceuticals field to develop a tailored response strategy for the 1 pending office action.
Because the company is only interacting with 1 distinct art unit, the administrative complexity of the portfolio is low. The focus on 1 distinct art unit within the Biotechnology & Pharmaceuticals area allows for a concentrated legal strategy. The outcome of the current prosecution will likely be determined by the specific interactions between the company and the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAIDHA, TEKCHAND | 1 | 82.9% | +14.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17768834 | GENETICALLY MODIFIED HOST CELLS PRODUCING BENZYLISOQUINOLINE ALKALOIDS | SAIDHA, TEKCHAND | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17768834 | GENETICALLY MODIFIED HOST CELLS PRODUCING BENZYLISOQUINOLINE ALKALOIDS | SAIDHA, TEKCHAND | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17768834 | GENETICALLY MODIFIED HOST CELLS PRODUCING BENZYLISOQUINOLINE ALKALOIDS | SAIDHA, TEKCHAND | 1652 | §112 | Non-Final OA | — | Pending | Apr 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial